Exhibit 99.1 Grace Therapeutics Announces Second Quarter 2026 Financial Results, Provides Business Update Announced U.S. Food and Drug Administration (FDA) Acceptance for Review of New Drug Application (NDA) for GTx-104 FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Phase 3 STRIVE-ON Safety Trial Data Presented at 2025 Neurocritical Care Annual Meeting Granted Sixth U.S. Pat ...